IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

aflibercept Injection

aflibercept Injection
For Intravitreal Injection Initial U.S. Approval 2011

Facts about aflibercept Injection

Approval Date: 2011
Proprietary Name: On Request
Active Ingredient(s): aflibercept
Dosage Forms And Strengths: 40 mg/mL solution for intravitreal injection in a single-use vial
Company: Regeneron Pharmaceuticals, Bayer
Diseases: wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “aflibercept Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For aflibercept Injection

Approved accessible "aflibercept Injection"

Eylea is a medicine used to treat adults with:

  • the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling;
  • impaired vision due to macular oedema (swelling) that follows blockage of either the main vein carrying blood from the retina (known as central retinal vein occlusion, CRVO) or of smaller branch veins (known as branch retinal vein occlusion, BRVO);
  • impaired vision due to macular oedema caused by diabetes;
  • impaired vision due to myopic choroidal neovascularisation (a severe type of short-sightedness where the eyeball continues to grow, becoming longer than it should be).

How can 1 go about obtaining aflibercept Injection?

If aflibercept Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

EYLEA (aflibercept) Injection For Intravitreal Injection Initial U.S. Approval 2011


Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398